About Cara Therapeutics
Cara Therapeutics is a company based in New York (United States) founded in 2004.. Cara Therapeutics has raised $51 million across 5 funding rounds from investors including MVM Partners, Rho Capital Partners and Alta Partners. The company has 79 employees as of December 31, 2022. Cara Therapeutics offers products and services including IPF Therapy and Liver Cancer Treatment. Cara Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others.
- Headquarter New York, United States
- Employees 79 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
$4.33 M943as on Dec 31, 2024
-
Net Profit
$-70.87 M40as on Dec 31, 2024
-
EBITDA
$-58.38 M52as on Dec 31, 2024
-
Total Equity Funding
$51 M (USD)
in 5 rounds
-
Latest Funding Round
$100 K (USD), Post-IPO
Dec 11, 2014
-
Investors
MVM Partners
& 7 more
-
Employee Count
79
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cara Therapeutics
Cara Therapeutics offers a comprehensive portfolio of products and services, including IPF Therapy and Liver Cancer Treatment. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatment for idiopathic pulmonary fibrosis through research trials.
Therapy targeting liver cancer in advanced stages.
Unlock access to complete
Unlock access to complete
Leadership Team
10 people
Product Management Team
4 people
Finance and Accounting
3 people
Software Development Team
2 people
Data Analysis and Operations Team
2 people
Legal and Compliance
1 people
Human Resources and Administration
1 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of Cara Therapeutics
Cara Therapeutics has successfully raised a total of $51M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 thousand completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $100,003
-
First Round
First Round
(21 Dec 2005)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2014 | Amount | Post-IPO - Cara Therapeutics | Valuation |
investors |
|
| Jul, 2010 | Amount | Series D - Cara Therapeutics | Valuation | Rho Capital Partners , SWIP | |
| Jul, 2008 | Amount | Series C - Cara Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Cara Therapeutics
Cara Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include MVM Partners, Rho Capital Partners and Alta Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech startups are invested in by Rho Capital Partners.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on healthcare companies
|
Founded Year | Domain | Location | |
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Cara Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Cara Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Cara Therapeutics Comparisons
Competitors of Cara Therapeutics
Cara Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Flexion Therapeutics, Univercells, Sutro Biopharma and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Cara Therapeutics
Frequently Asked Questions about Cara Therapeutics
When was Cara Therapeutics founded?
Cara Therapeutics was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Where is Cara Therapeutics located?
Cara Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Who is the current CEO of Cara Therapeutics?
Christopher Posner is the current CEO of Cara Therapeutics.
Is Cara Therapeutics a funded company?
Cara Therapeutics is a funded company, having raised a total of $51M across 5 funding rounds to date. The company's 1st funding round was a Series C of $12.3M, raised on Dec 21, 2005.
How many employees does Cara Therapeutics have?
As of Dec 31, 2022, the latest employee count at Cara Therapeutics is 79.
What is the annual revenue of Cara Therapeutics?
Annual revenue of Cara Therapeutics is $4.33M as on Dec 31, 2024.
What does Cara Therapeutics do?
Cara Therapeutics is developing cannabinoid and opioid receptor targeting therapeutics for pain relief and inflammatory diseases. Its proprietary technology DimerScreen identifies molecular structures that interact with the G-Protein-Coupled Receptors (GPCRS). Its lead candidate, CR845, is a peripheral kappa-opioid receptor agonist and is in Phase III trials for acute postoperative pain and pruritis. The company is also developing cannabinoid receptor agonists for pain relief.
Who are the top competitors of Cara Therapeutics?
Cara Therapeutics's top competitors include Sutro Biopharma, Flexion Therapeutics and Avidity Biosciences.
What products or services does Cara Therapeutics offer?
Cara Therapeutics offers IPF Therapy and Liver Cancer Treatment.
Who are Cara Therapeutics's investors?
Cara Therapeutics has 8 investors. Key investors include MVM Partners, Rho Capital Partners, Alta Partners, Connecticut Innovations, and SWIP.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.